Lin Yu-Hsin
Chief Executive Officer
Lin Yu-Hsin has filed 4 SEC Form 4 filings (26 transaction rows) across 1 company, with disclosures dating back to 2026. 4 of those filings fall inside the rolling window. Most recent filing: Sep 9, 2026.
On the most recent filing, Lin Yu-Hsin is listed as Chief Executive Officer at BELITE BIO, INC. Inside the rolling window, Lin Yu-Hsin reported no open-market purchases and 4 open-market sales totaling $20.8M in BLTE. The largest disclosed transaction in the window is a sale of 74,435 BLTE shares on Sep 4, 2026, worth $14.0M.
Companies traded
Other insiders at BLTE
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$20.8M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Lin Yu-Hsin made?
Lin Yu-Hsin has filed 4 SEC Form 4 filings (26 transaction rows) across 1 company since 2026.
Which companies does Lin Yu-Hsin trade?
Lin Yu-Hsin has filed SEC Form 4 disclosures for 1 company, including BLTE.
When was Lin Yu-Hsin's most recent SEC Form 4 filing?
Lin Yu-Hsin's most recent SEC Form 4 filing on Tracefour is dated Sep 9, 2026.
What is Lin Yu-Hsin's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Lin Yu-Hsin is listed as Chief Executive Officer.
What is Lin Yu-Hsin's total buy and sell value in the current window?
Inside the rolling retention window, Lin Yu-Hsin bought $0 and sold $20.8M based on SEC Form 4 filings.
What was Lin Yu-Hsin's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 74,435 BLTE shares on 2026-09-04, worth $14.0M, per SEC Form 4 filings.